{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:32:09Z","timestamp":1790526729667,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1803,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","exphem.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.exphem.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:46:24Z","timestamp":1493340384000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications"],"prefix":"10.1016","volume":"51","author":[{"given":"Irina","family":"Sadovnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Eisenwort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2017.04.003_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib3","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2017.04.003_bib5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib6","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1535-6108(02)00025-9","article-title":"Perspectives on the development of a molecularly targeted agent","volume":"1","author":"Druker","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2017.04.003_bib8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2017.04.003_bib12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10245330500234195","article-title":"Evolving molecular therapy for chronic myeloid leukaemia\u2014Are we on target?","volume":"10","author":"Copland","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.exphem.2017.04.003_bib14","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2017.04.003_bib15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","article-title":"Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate","volume":"116","author":"Jiang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: Mutations and beyond","volume":"47","author":"La Rosee","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.exphem.2017.04.003_bib17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib18","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.exphem.2017.04.003_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2017.04.003_bib21","first-page":"534","article-title":"New tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"90","author":"Martinelli","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2017.04.003_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1517\/14656566.2014.882898","article-title":"Bosutinib: A review of preclinical and clinical studies in chronic myelogenous leukemia","volume":"15","author":"Rusconi","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.exphem.2017.04.003_bib23","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib25","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib26","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib27","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2017.04.003_bib29","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2017.04.003_bib30","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1182\/blood-2008-08-077941","article-title":"Stem cell concepts renew cancer research","volume":"112","author":"Dick","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib31","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V88.6.2162.bloodjournal8862162","article-title":"Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia","volume":"88","author":"Petzer","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V97.3.720","article-title":"Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in\u00a0vitro in association with up-regulation of expression of interleukin-3","volume":"97","author":"Holyoake","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/leu.2008.392","article-title":"The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence","volume":"23","author":"Bruns","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib35","doi-asserted-by":"crossref","first-page":"715","DOI":"10.18632\/oncotarget.990","article-title":"Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations","volume":"4","author":"Gerber","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.04.003_bib36","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSCs) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia","volume":"44","author":"Valent","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.exphem.2017.04.003_bib38","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/leu.2008.246","article-title":"Targeting the leukemic stem cell: The Holy Grail of leukemia therapy","volume":"23","author":"Misaghian","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy","volume":"4","author":"Essers","year":"2010","journal-title":"Mol Oncol"},{"key":"10.1016\/j.exphem.2017.04.003_bib41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/156800911793743655","article-title":"Targeting of leukemia-initiating cells to develop curative drug therapies: Straightforward but nontrivial concept","volume":"11","author":"Valent","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2017.04.003_bib42","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2013-07-517847","article-title":"The IL-2\/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells","volume":"123","author":"Kobayashi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-15-0767","article-title":"Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML","volume":"22","author":"Sadovnik","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2017.04.003_bib44","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2017.04.003_bib45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/S0301-472X(00)00545-2","article-title":"Chronic myelogenous leukemia primitive hematopoietic progenitors demonstrate increased sensitivity to growth factor-induced proliferation and maturation","volume":"28","author":"Bhatia","year":"2000","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2017.04.003_bib46","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia","volume":"16","author":"Holyoake","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2008.364","article-title":"The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells","volume":"23","author":"Belloc","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190500272507","article-title":"Detection of molecular targets on the surface of CD34+\/CD38- stem cells in various myeloid malignancies","volume":"47","author":"Florian","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2017.04.003_bib49","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1038\/bcj.2011.35","article-title":"Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell\/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia","volume":"1","author":"Wisniewski","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2017.04.003_bib50","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood.V128.22.4234.4234","article-title":"Evaluation of cell surface markers and targets in leukemic stem cells (LSCs) reveals distinct expression profiles, unique drug effects, and specific checkpoint regulation in AML LSCs and CML LSCs","volume":"128","author":"Sadovnik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib51","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/sj.leu.2401875","article-title":"Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells","volume":"14","author":"D\u00fcrig","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib52","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/stemcells.20-3-259","article-title":"Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1","volume":"20","author":"Peled","year":"2002","journal-title":"Stem Cells"},{"key":"10.1016\/j.exphem.2017.04.003_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3324\/haematol.2010.035006","article-title":"CD34(+)\/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab\/ozogamicin","volume":"97","author":"Herrmann","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2017.04.003_bib54","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2017.04.003_bib55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.V126.23.49.49","article-title":"CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia","volume":"126","author":"Kinstrie","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib56","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib57","doi-asserted-by":"crossref","first-page":"33016","DOI":"10.18632\/oncotarget.9108","article-title":"Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: Patient-subgroups, prognostic impact, and technical aspects","volume":"7","author":"Culen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2017.04.003_bib58","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrc3368","article-title":"Cancer stem cell definitions and terminology: The devil is in the details","volume":"12","author":"Valent","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.exphem.2017.04.003_bib59","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-12-3678","article-title":"Heterogeneity of neoplastic stem cells: Theoretical, functional, and clinical implications","volume":"73","author":"Valent","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2017.04.003_bib60","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib61","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib62","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood.V70.6.1872.1872","article-title":"Human blood basophils display a unique phenotype including activation linked membrane structures","volume":"70","author":"Stain","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2017.04.003_bib63","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/leu.2015.353","article-title":"CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia","volume":"30","author":"Jena","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2017.04.003_bib64","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci Transl Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17301352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X17301352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T05:26:40Z","timestamp":1654925200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X17301352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":64,"alternative-id":["S0301472X17301352"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2017.04.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}